Alvotech (ALVO)

Market Cap	2.88B
Revenue (ttm)	491.98M
Net Income (ttm)	-231.86M
Shares Out	301.81M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	54.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,106
Open	10.25
Previous Close	10.36
Day's Range	9.55 - 9.75
52-Week Range	9.15 - 14.76
Beta	-0.16
Analysts	Buy
Price Target	18.00 (+88.48%)
Earnings Date	Mar 26, 2025

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 999
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO
• Website: https://www.alvotech.com

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Analyst Forecast

According to one analyst, the rating for ALVO stock is "Buy" and the 12-month stock price forecast is $18.0.

Price Target

$18.0

(88.48% upside)

Analyst Consensus: Buy